Delving into the Latest Updates on Enumeral Biomedical Holdings, Inc. with Synapse

Overview

AbstractWe have previously described the identification of more than 300 anti-PD-1 monoclonal antibody candidates using Enumeral's proprietary single cell immune-profiling technology, on which our antibody discovery platform is based. Bioinformatics analysis of heavy chain CDR3 sequences show they comprise diverse families, encompassing 26 phylogenetic clades. Functional studies from cell-based, ex vivo human assays led to the discovery of two distinct lead candidates, 244C8 and 388D4. The former represents a novel class of anti-PD-1 antibodies with a potentially differentiated mechanism of action, as they appear not to compete with currently marketed antibodies for PD-1 nor do they compete with PD-L1 for PD-1 binding. Further, antibodies from the 244C8 family elicit both a higher T cell activation and an increased expression of the high affinity IL-2 receptor CD25 than currently marketed anti-PD-1 antibodies in ex vivo human cell based assays. Lead antibodies from both anti-PD-1 classes, 244C8 and 388D4, have been humanized for preclinical testing in preparation for Phase 1 clinical studies. Here we describe the in vivo efficacy testing of these two antibodies in a human PDX tumorgraft model derived from a core needle biopsy of a patient with metastatic non-small cell lung carcinoma (LG1306). Direct testing of the anti-human PD-1 antibodies was made possible by the use of immune-humanized NSG mice. Pembrolizumab, a currently marketed anti-PD-1 antibody, served as control, along with vehicle alone. Treatment with each of the humanized lead PD-1 antibodies, 388D4 and 244C8, was well tolerated at 5 mg/kg and led to significant tumor growth inhibition over a 28-day study period. Both showed equivalent efficacy to pembrolizumab with tumor growth inhibition (%TGI) at 40% and 38% respectively compared to 37% for pembrolizumab. All three treatment agents showed significant tumor growth inhibition relative to vehicle, with Student T-test p values < 0.003 at end of study assessment. These results show that, contrary to expectation, competition for binding to PD-L1 ligand by an anti-PD-1 antibody is not a pre-requisite for functional efficacy in vivo, as we observed with 244C8. In addition to the in vivo efficacy studies, we will report on post-treatment analyses of all treatment cohorts by immunohistochemistry and RNAseq of the tumor samples, immunoprofiling analysis of tumor infiltrating lymphocytes (TILs) from all treatment cohorts, as well as donor-specific differences that influence response to treatment.Citation Format: Felix Scheuplein, Sheila Ranganath, Bin Feng, Thomas McQuade, Lei Wang, Vikki Spaulding, Sri Vadde, Shanu Mehta, Maria Isabel Chiu, Cokey Nguyen. Two novel anti-PD-1 antibodies, 244C8 and 388D4, elicit in vivo antitumor efficacy in a lung PDX tumorgraft in immuno-humanized NSG mice. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4871.

1

News (Medical) associated with Enumeral Biomedical Holdings, Inc.

20 Mar 2015

·www.biospace.com

Enumeral Biomedical Reports Fourth Quarter And Year-End 2014 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014. Help employers find you! Check out all the jobs and post your resume.

Financial Statement

100 Deals associated with Enumeral Biomedical Holdings, Inc.

Login to view more data

100 Translational Medicine associated with Enumeral Biomedical Holdings, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data